Skip to main
CODX

Co-Diagnostics (CODX) Stock Forecast & Price Target

Co-Diagnostics (CODX) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Co-Diagnostics Inc is well-positioned for growth due to the expanding market for respiratory infectious disease diagnostics in the Middle East, significantly bolstered by investments from Saudi Arabia. The strategic partnership with Arabian Eagle Manufacturing to develop and commercialize Co-Dx technologies in the region enhances the company's operational capabilities and market reach. Furthermore, the ongoing advancements of the Co-Dx PCR platform and the development of a proprietary sample preparation instrument indicate the company's commitment to improving access to affordable diagnostics, potentially leading to increased market share and revenue opportunities in various medical applications.

Bears say

Co-Diagnostics Inc faces significant risks that could adversely impact its financial stability, including potential failures in clinical evaluations and challenges in securing regulatory clearance for its diagnostic tests and instruments in the U.S. The company reported a minimal revenue of $145,000 for the third quarter of 2025, contrasted by a substantial net loss of $5.9 million, translating to a loss of $0.16 per share, highlighting ongoing financial struggles. Additionally, concerns over dilution risk suggest that any future capital raises may result in unfavorable terms, further complicating the company’s financial outlook.

Co-Diagnostics (CODX) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Co-Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Co-Diagnostics (CODX) Forecast

Analysts have given Co-Diagnostics (CODX) a Buy based on their latest research and market trends.

According to 3 analysts, Co-Diagnostics (CODX) has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Co-Diagnostics (CODX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.